The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy... by Andrea J. Luker, Laura J. Graham, Timothy M. Smith, Carmen Camarena, Matt P. Zellner, Jamie-Jean S. Gilmer, Sheela R. Damle, Daniel H. Conrad, Harry D. Bear, Rebecca K. Martin

Get full text